Greater Combined Reductions of HbA1c ≥ 1.0% and Body Weight Loss ≥ 5.0% or ≥ 10.0% with Orally Administered Semaglutide Versus Comparators
| dc.contributor.author | Dungan, Kathleen M. | |
| dc.contributor.author | Bardtrum, Lars | |
| dc.contributor.author | Christiansen, Erik | |
| dc.contributor.author | Eliasson, Johanna | |
| dc.contributor.author | Mellbin, Linda | |
| dc.contributor.author | Woo, Vincent C. | |
| dc.contributor.author | Vilsbøll, Tina | |
| dc.date.accessioned | 2023-06-07T14:11:42Z | |
| dc.date.available | 2023-06-07T14:11:42Z | |
| dc.date.issued | 2023-05-31 | |
| dc.date.updated | 2023-06-01T03:27:44Z | |
| dc.description.abstract | Abstract Introduction A post hoc analysis of the PIONEER 1–5 and 8 trials assessed the clinically relevant composite endpoints of HbA1c (glycated haemoglobin) reduction ≥ 1% and body weight loss of ≥ 5% or ≥ 10% with orally administered semaglutide versus comparators. Methods In the PIONEER trials, people with type 2 diabetes were randomised to orally administered semaglutide versus placebo (PIONEER 1, 4, 5 and 8), empagliflozin (PIONEER 2), sitagliptin (PIONEER 3) and liraglutide (PIONEER 4) for 26–78 weeks. This analysis assessed the proportion of people achieving an HbA1c reduction of ≥ 1% and body weight loss of ≥ 5% at week 26 and at end of treatment, and the proportion of people achieving an HbA1c reduction of ≥ 1% and body weight loss of ≥ 10% at end of treatment. Results Overall, 3506 people in PIONEER 1–5 and 8 were included. At week 26 and at end of treatment, odds of achieving the composite endpoint of an HbA1c reduction of ≥ 1% and body weight loss of ≥ 5% were significantly greater with orally administered semaglutide 14 mg than with placebo (PIONEER 1, 4, 5 and 8; all p < 0.0001), empagliflozin 25 mg (PIONEER 2, p < 0.0001), sitagliptin 100 mg (PIONEER 3, p < 0.0001) and liraglutide 1.8 mg (PIONEER 4, p < 0.0001). Odds of achieving the composite endpoint of HbA1c reduction of ≥ 1% and body weight loss of ≥ 10% at end of treatment were also significantly greater with orally administered semaglutide versus comparators. Conclusion In PIONEER 1–5 and 8, odds of achieving clinically relevant reductions in both HbA1c and body weight were significantly greater with orally administered semaglutide versus comparators. Graphical Abstract | en_US |
| dc.identifier.doi | 10.1007/s13300-023-01413-5 | |
| dc.identifier.uri | https://doi.org/10.1007/s13300-023-01413-5 | |
| dc.identifier.uri | http://hdl.handle.net/1993/37377 | |
| dc.language.iso | eng | en_US |
| dc.language.rfc3066 | en | |
| dc.publisher | SpringerOpen | en_US |
| dc.rights | open access | en_US |
| dc.rights.holder | The Author(s) | |
| dc.title | Greater Combined Reductions of HbA1c ≥ 1.0% and Body Weight Loss ≥ 5.0% or ≥ 10.0% with Orally Administered Semaglutide Versus Comparators | en_US |
| dc.type | journal article | en_US |
| local.author.affiliation | Rady Faculty of Health Sciences::Max Rady College of Medicine::Department of Internal Medicine | en_US |
| oaire.citation.title | Diabetes Therapy | en_US |